Spruce Biosciences, Inc.
SPRBNASDAQHealthcare● Active
$49.32
$-1.11(-2.20%)
Market Cap$67668470
P/E Ratio—
52W High$838.125
52W Low$7
Spruce Biosciences, Inc. (SPRB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SPRB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$8.94
Est. -$7.32 · -22.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
SPRB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$5.17 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$7.32 | -$8.94 | -22.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$12.87 | -$9.58 | +25.6% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$15.56 | -$14.58 | +6.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$18.05 | -$3.50 | +80.6% | — | — | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$18.80 | -$24.06 | -28.0% | — | $0.00B | — |
| ▲ Q2 FY2025 | Apr 2, 2025 | -$0.24 | -$0.23 | +4.2% | $0.00B | $0.00B | -21.2% |
| ▲ Q4 FY2024 | Nov 11, 2024 | -$20.30 | -$15.79 | +22.2% | $0.00B | $0.00B | +80.6% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$5.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$8.94
EPS Est.
-$7.32
EPS Surpr.
-22.1%
Revenue
—
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$9.58
EPS Est.
-$12.87
EPS Surpr.
+25.6%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$14.58
EPS Est.
-$15.56
EPS Surpr.
+6.3%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$3.50
EPS Est.
-$18.05
EPS Surpr.
+80.6%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$24.06
EPS Est.
-$18.80
EPS Surpr.
-28.0%
Revenue
—
Q2 FY2025
Apr 2, 2025Beat
EPS Actual
-$0.23
EPS Est.
-$0.24
EPS Surpr.
+4.2%
Revenue
$0.00B
Q4 FY2024
Nov 11, 2024Beat
EPS Actual
-$15.79
EPS Est.
-$20.30
EPS Surpr.
+22.2%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-3.72 | $-3.72 | $-3.72 | 1 |
| Q3 FY2027 | $21.36 | $21.36 | $21.36 | 1 |
| Q2 FY2027 | $-5.33 | $-5.33 | $-5.33 | 1 |
| Q1 FY2027 | $-5.20 | $-5.20 | $-5.20 | 1 |
| Q4 FY2026 | $-5.14 | $-5.14 | $-5.14 | 1 |
| Q3 FY2026 | $-5.15 | $-4.95 | $-4.73 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -22.1% | $56.67 | $57.55 | +1.55% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +25.6% | $55.87 | $62.11 | +11.17% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +6.3% | $127.00 | $115.61 | -8.97% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +80.6% | $9.30 | $8.75 | -5.91% |
| ▼ Q2 FY2025 | May 6, 2025 | -28.0% | $5.40 | $5.33 | -1.30% |
| ▲ Q2 FY2025 | Apr 2, 2025 | +4.2% | $20.10 | $21.98 | +9.35% |
| ▲ Q4 FY2024 | Nov 11, 2024 | +22.2% | $40.20 | $39.98 | -0.55% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +33.3% | $32.85 | $31.35 | -4.57% |
Q2 FY2026+1.55%
Report Date
May 13, 2026
EPS Beat/Miss
-22.1%
Price Before
$56.67
Price After
$57.55
Q1 FY2026+11.17%
Report Date
Mar 9, 2026
EPS Beat/Miss
+25.6%
Price Before
$55.87
Price After
$62.11
Q4 FY2025-8.97%
Report Date
Nov 10, 2025
EPS Beat/Miss
+6.3%
Price Before
$127.00
Price After
$115.61
Q3 FY2025-5.91%
Report Date
Aug 14, 2025
EPS Beat/Miss
+80.6%
Price Before
$9.30
Price After
$8.75
Q2 FY2025-1.30%
Report Date
May 6, 2025
EPS Beat/Miss
-28.0%
Price Before
$5.40
Price After
$5.33
Q2 FY2025+9.35%
Report Date
Apr 2, 2025
EPS Beat/Miss
+4.2%
Price Before
$20.10
Price After
$21.98
Q4 FY2024-0.55%
Report Date
Nov 11, 2024
EPS Beat/Miss
+22.2%
Price Before
$40.20
Price After
$39.98
Q3 FY2024-4.57%
Report Date
Aug 12, 2024
EPS Beat/Miss
+33.3%
Price Before
$32.85
Price After
$31.35
Avg Beat Reaction+0.09%
Avg Miss Reaction+0.13%
Beat Rate6 / 8 quarters
Largest Move+11.17% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SPRB ends December
Spruce Biosciences, Inc. (SPRB) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-8.94 — missing the analyst consensus of $-7.32 by -22.1%. The next SPRB earnings date is expected around September 1, 2026.
Each quarter, investors track SPRB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SPRB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SPRB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SPRB earnings · 5 questionsSpruce Biosciences, Inc.'s next earnings report is expected around September 1, 2026. SPRB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SPRB historically reports after market close (AMC).
SPRB earnings datewhen is SPRB earningsSPRB next earnings datewhen does SPRB report earningsSPRB earnings calendar
▸ Source: FMP · Spruce Biosciences, Inc. SEC filings · US GAAP · Spruce Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026